↓ Skip to main content

Stem cell approaches for diabetes: towards beta cell replacement

Overview of attention for article published in Genome Medicine, September 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)

Mentioned by

patent
1 patent
facebook
2 Facebook pages

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
132 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Stem cell approaches for diabetes: towards beta cell replacement
Published in
Genome Medicine, September 2011
DOI 10.1186/gm277
Pubmed ID
Authors

Gordon C Weir, Claudia Cavelti-Weder, Susan Bonner-Weir

Abstract

Stem cells hold great promise for pancreatic beta cell replacement therapy for diabetes. In type 1 diabetes, beta cells are mostly destroyed, and in type 2 diabetes beta cell numbers are reduced by 40% to 60%. The proof-of-principle that cellular transplants of pancreatic islets, which contain insulin-secreting beta cells, can reverse the hyperglycemia of type 1 diabetes has been established, and there is now a need to find an adequate source of islet cells. Human embryonic stem cells can be directed to become fully developed beta cells and there is expectation that induced pluripotent stem (iPS) cells can be similarly directed. iPS cells can also be generated from patients with diabetes to allow studies of the genomics and pathogenesis of the disease. Some alternative approaches for replacing beta cells include finding ways to enhance the replication of existing beta cells, stimulating neogenesis (the formation of new islets in postnatal life), and reprogramming of pancreatic exocrine cells to insulin-producing cells. Stem-cell-based approaches could also be used for modulation of the immune system in type 1 diabetes, or to address the problems of obesity and insulin resistance in type 2 diabetes. Herein, we review recent advances in our understanding of diabetes and beta cell biology at the genomic level, and we discuss how stem-cell-based approaches might be used for replacing beta cells and for treating diabetes.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 1 <1%
Nepal 1 <1%
Norway 1 <1%
Canada 1 <1%
Egypt 1 <1%
Iran, Islamic Republic of 1 <1%
Belgium 1 <1%
Japan 1 <1%
United States 1 <1%
Other 0 0%
Unknown 123 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 34 26%
Student > Master 25 19%
Researcher 18 14%
Student > Bachelor 15 11%
Student > Postgraduate 6 5%
Other 18 14%
Unknown 16 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 44 33%
Medicine and Dentistry 28 21%
Biochemistry, Genetics and Molecular Biology 25 19%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Economics, Econometrics and Finance 4 3%
Other 9 7%
Unknown 18 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2015.
All research outputs
#7,960,512
of 25,374,647 outputs
Outputs from Genome Medicine
#1,216
of 1,585 outputs
Outputs of similar age
#45,425
of 142,692 outputs
Outputs of similar age from Genome Medicine
#12
of 15 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,585 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.8. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 142,692 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.